Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bennett Levitan

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Drugs & Aging|March 31, 2025
Benefit-Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous ThromboembolismPaul P Dobesh, Albert A Volkl, Ákos Ferenc Pap, et al.
Value in Health Regional Issues|April 27, 2018
Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with Anticoagulants in Atrial Fibrillation-evidence from the United States and JapanKen Okumura, Hiroshi Inoue, Masahiro Yasaka, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 23, 2022
The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trialRobert J Fox, Tommi Tervonen, Andrea Phillips-Beyer, et al.
The Patient|December 12, 2023
Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry SurveyCathy Anne Pinto, Tommi Tervonen, Cecilia Jimenez-Moreno, et al.
Journal of the American Heart Association|November 10, 2021
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINERGary E Raskob, Alex C Spyropoulos, Theodore E Spiro, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Patient Engagement at a Tipping Point-The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders: Insights From the DIA Conference, "Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products"Meredith Y Smith, Tarek A Hammad, Marilyn Metcalf, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials ProjectBennett Levitan, Kenneth Getz, Eric L Eisenstein, et al.
Clinical Pharmacology and Therapeutics|March 20, 2024
A Benefit-Risk Conceptual Framework for Biologic Use During Pregnancy: A Mini-ReviewLaura M Bozzi, Melanie H Jacobson, Emily Yost, et al.
Journal of the American Heart Association|April 2, 2024
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD TrialZhong Yuan, Bennett Levitan, Hsiaowei Deng, et al.
Therapeutic Innovation & Regulatory Science|September 30, 2020
Development and Application of a Patient Group Engagement Prioritization Tool for Use in Medical Product DevelopmentBrian Perry, Carrie Dombeck, Jaye Bea Smalley, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Drugs & Aging|March 31, 2025
Benefit-Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous ThromboembolismPaul P Dobesh, Albert A Volkl, Ákos Ferenc Pap, et al.
Value in Health Regional Issues|April 27, 2018
Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with Anticoagulants in Atrial Fibrillation-evidence from the United States and JapanKen Okumura, Hiroshi Inoue, Masahiro Yasaka, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 23, 2022
The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trialRobert J Fox, Tommi Tervonen, Andrea Phillips-Beyer, et al.
The Patient|December 12, 2023
Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry SurveyCathy Anne Pinto, Tommi Tervonen, Cecilia Jimenez-Moreno, et al.
Journal of the American Heart Association|November 10, 2021
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINERGary E Raskob, Alex C Spyropoulos, Theodore E Spiro, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Patient Engagement at a Tipping Point-The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders: Insights From the DIA Conference, "Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products"Meredith Y Smith, Tarek A Hammad, Marilyn Metcalf, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials ProjectBennett Levitan, Kenneth Getz, Eric L Eisenstein, et al.
Clinical Pharmacology and Therapeutics|March 20, 2024
A Benefit-Risk Conceptual Framework for Biologic Use During Pregnancy: A Mini-ReviewLaura M Bozzi, Melanie H Jacobson, Emily Yost, et al.
Journal of the American Heart Association|April 2, 2024
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD TrialZhong Yuan, Bennett Levitan, Hsiaowei Deng, et al.
Therapeutic Innovation & Regulatory Science|September 30, 2020
Development and Application of a Patient Group Engagement Prioritization Tool for Use in Medical Product DevelopmentBrian Perry, Carrie Dombeck, Jaye Bea Smalley, et al.
Pageof 6